TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE

Patent metadata

Field	Value
Publication number	US-2018333373-A1
Application number	US-201815873540-A
Country	US
Kind code	A1
Filing date	Jan 17, 2018
Priority date	Sep 16, 2002
Publication date	Nov 22, 2018
Grant date	—

Abstract

Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

First claim

1 . A method for treating obesity, the method comprising administering to a patient in need of treatment a therapeutically effective amount of a compound of formula PQ:

or a salt thereof.

2 . A method according to claim 1 , wherein the compound of formula PQ is selected from formula P and Q:

or a salt thereof.

3 . A method according to claim 1 , wherein the compound of formula PQ is (1S,4R)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine or a salt thereof.

4 . A method according to claim 1 , wherein the compound of formula PQ is (1R,4S)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine or a salt thereof.

5 . A method according to claim 1 , wherein the compound of formula PQ is (1S,4R)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine hydrochloride.

6 . A method according to claim 1 , wherein the compound of formula PQ is (1R,4S)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine hydrochloride.

Assignees

• Sunovion Pharmaceuticals Inc

Inventors

• JERUSSI Thomas
• Fang Qun Kevin
• Currie Mark G

Classifications

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07C2602/10

  the other ring being six-membered, e.g. tetraline · CPC title

• A61K31/135 Primary

  having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title

• C07C211/42

  with six-membered aromatic rings being part of the condensed ring systems · CPC title